These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 30036534)

  • 1. Evaluation and translation of combination therapies in oncology - A quantitative approach.
    Cardilin T; Almquist J; Jirstrand M; Gabrielsson J
    Eur J Pharmacol; 2018 Sep; 834():327-336. PubMed ID: 30036534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based Evaluation of Radiation and Radiosensitizing Agents in Oncology.
    Cardilin T; Almquist J; Jirstrand M; Zimmermann A; El Bawab S; Gabrielsson J
    CPT Pharmacometrics Syst Pharmacol; 2018 Jan; 7(1):51-58. PubMed ID: 29218836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Static Concentration Curves in Combination Therapy.
    Cardilin T; Almquist J; Jirstrand M; Sostelly A; Amendt C; El Bawab S; Gabrielsson J
    AAPS J; 2017 Mar; 19(2):456-467. PubMed ID: 27681102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents.
    Cardilin T; Almquist J; Jirstrand M; Zimmermann A; Lignet F; El Bawab S; Gabrielsson J
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1159-1173. PubMed ID: 30976845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncology.
    Baaz M; Cardilin T; Lignet F; Zimmermann A; El Bawab S; Gabrielsson J; Jirstrand M
    BMC Cancer; 2023 May; 23(1):409. PubMed ID: 37149596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response modeling improves selection of radiation and radiosensitizer combinations.
    Cardilin T; Almquist J; Jirstrand M; Zimmermann A; Lignet F; El Bawab S; Gabrielsson J
    J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):167-178. PubMed ID: 34623558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixture dynamics: Combination therapy in oncology.
    Gabrielsson J; Gibbons FD; Peletier LA
    Eur J Pharm Sci; 2016 Jun; 88():132-46. PubMed ID: 27050307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guiding model-driven combination dose selection using multi-objective synergy optimization.
    Gevertz JL; Kareva I
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1698-1713. PubMed ID: 37415306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts.
    Rose WC; Wild R
    Clin Cancer Res; 2004 Nov; 10(21):7413-7. PubMed ID: 15534118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
    Teicher BA
    Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
    Tonra JR; Prewett M; Corcoran E; Hicklin DJ; Zhu Z
    Methods Mol Biol; 2009; 525():545-57, xv. PubMed ID: 19252838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
    Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
    Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.